UK markets open in 30 minutes
  • NIKKEI 225

    27,885.87
    +65.47 (+0.24%)
     
  • HANG SENG

    19,384.81
    -133.48 (-0.68%)
     
  • CRUDE OIL

    77.53
    +0.60 (+0.78%)
     
  • GOLD FUTURES

    1,782.30
    +1.00 (+0.06%)
     
  • DOW

    33,947.10
    -482.78 (-1.40%)
     
  • BTC-GBP

    13,962.22
    -309.12 (-2.17%)
     
  • CMC Crypto 200

    401.92
    -9.29 (-2.26%)
     
  • ^IXIC

    11,239.94
    -221.56 (-1.93%)
     
  • ^FTAS

    4,143.21
    +4.40 (+0.11%)
     

Trinity Biotech Announces Quarter 2 2022 Financial Results And Preliminary Q3 2022 Revenue Guidance

Trinity Biotech plc
Trinity Biotech plc

DUBLIN, Ireland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended June 30, 2022 and preliminary guidance with respect to Q3 revenues.

Summary Highlights:

  • Total revenues for Q2 2022 were $18.5m.

  • Excluding our Covid focused PCR Viral Transport Media (“VTM”) products, Q2 2022 revenues of $18.0m were broadly flat compared to Q2 2021 and were up 7% compared to Q1 2022. A strong YoY increase in revenues in our diabetes A1c product line revenues of over 25% offset a decline in legacy infectious disease product demand in Asia due to continuing COVID-19 lockdowns.

  • Preliminary estimates for Q3 2022 indicate expected revenues of between $19m to $20m. Q3 Global Health HIV orders for Africa, which are often difficult to predict, increased compared to Q2 2022 and we expect our HIV point of care (“PoC”) revenue to grow over 30% on a QoQ basis. Fitzgerald continues to perform well with a 25% QoQ revenue growth profile expected.

  • In May 2022, the Company announced the closing of a $45.2m investment from MiCo Ltd (“MiCo”). The investment consists of an equity investment of $25.2m acquired for $2.25 per ADS and a seven-year, unsecured junior convertible note of $20.0m with an interest rate of 1.5% and mandatory conversion price of $3.24.

  • As part of its ongoing balance sheet restructuring, the Company made a partial early repayment of its term loan with the Perceptive group in May 2022. To date, this partial repayment has saved the Company cash interest expense of $2.3m.

  • In late August 2022 the Company submitted its 510k submission to the FDA seeking US regulatory approval of its Premier Resolution Haemoglobin Variants instrument. Subject to FDA approval, commercial sales are expected to begin by Q2 2023.

  • The Company is finalising the development of a lower cost, mid throughput A1c instrument that leverages the core consumables technology from our existing Premier 9210 instrument, targeting developing markets. We are also working on the launch of a clinical laboratory reader/processor range to complement our autoimmune products for a 2023 launch.

  • Since World Health Organisation approval in February 2022 of our TrinScreen HIV product, the relevant Kenyan Ministry of Health task force recommended TrinScreen as the first line screening test for Kenya’s new HIV testing algorithm.

  • Platform optimisation actions to date have resulted in a more efficient workforce. Our average headcount in the six months ended June 30, 2022 was approximately 410 compared to over 500 in the six months ended June 30, 2021 and we expect total headcount to be under 400 by the end of 2022.  Trinity Biotech continues to focus on improving gross margin, earnings, and cash contribution from existing operations through focusing on operational efficiency.

  • The Company is undertaking a portfolio wide capital and talent allocation review emphasising maximizing return on capital and cash contribution.

  • Supply chain and commercial actions are underway to significantly optimise margins in our haemoglobins operation, including insourcing key elements of our consumable column manufacturing. We are also expanding manufacturing capacity at our Jamestown facility to address demand growth for our autoimmune products while also offsetting excess production capacity from the expected run off in demand for our legacy infectious disease products.

  • We have launched a strategic review of expansion opportunities in the Point of Care and decentralised testing markets to take advantage of rapidly evolving patient expectations and technology, new non-traditional market entrants and payor focus on controlling healthcare costs. We are actively exploring acquisition and partnership strategies in these areas aimed at accessing channel distribution, product innovation and user experience expertise and intend to make a substantial investment toward this effort over the next 18 months in our Buffalo, NY lab which is well positioned to serve the decentralised testing market because, unlike many other US labs, it is certified to process samples from all 50 US states.

  • The Company continues to focus on attracting and incentivising a world class leadership team with the recent appointment of Aris Kekedjian as CEO and Chairman, and by making further experienced hires to drive excellence in supply chain, regulatory compliance, business intelligence, corporate development and technology.

  • Trinity Biotech will be a presenter at the 2022 Piper Sandler Healthcare Conference on Thursday, December 1, 2022. Aris Kekedjian, Chairman and Chief Executive Officer, and John Gillard, Chief Financial Officer, will represent the Company and will also host a number of 1-on-1 meetings with investors.

Details

Quarter 2 Unaudited Results

Total revenues for Q2, 2022 were $18.5m which compares to $25.8m in Q2, 2021, a decrease of 28.6% and which were broken down as follows:

 

2021
Quarter 2

2022
Quarter 2



(Decrease)

 

US$’000

US$’000

%

Clinical Laboratory

23,885

16,624

(30.4%)

Point-of-Care

1,958

1,840

(6.0%)

Total

25,843

18,464

(28.6%)


Clinical Laboratory revenues were $16.6m, compared to $23.9m in Q2, 2021, representing a decrease of $7.3m or 30.4%. This decrease is mainly due to a reduction of approximately $7.4m in revenues from our PCR VTM products compared to Q2 2021. Sales volumes for PCR VTM products have decreased since the first half of 2021 due to a significant scaling down of PCR testing programs for Covid-19. In addition, there was an approximately $800k reduction in revenues in our legacy infectious disease product range compared to Q2 2021 as continuing COVID-19 lockdowns in Asia hampered demand for these products.

Our diabetes A1c revenues continue to grow with a $1.2m or 27% increase in revenues compared to Q2 2021 and we expect earnings from our A1c testing business to increase in the near term given our increasing instrument installed base and operational & strategic supply chain changes we began executing in Q3 2022 to reduce the cost of goods of our tests.

PoC revenues for Q2, 2022 decreased from $2.0m to $1.8m when compared to Q2, 2021, a decrease of 6.0%. This was mainly attributable to lower sales of HIV tests in Africa. Such fluctuations are a feature of the African HIV market which exhibits irregular ordering patterns from customers.

Gross profit for Q2, 2022 decreased from $11.0m to $6.5m when compared to Q2, 2021. The gross margin of 35.3% for Q2, 2022 was 7.4% lower the margin achieved in Q2, 2021, with the reduction largely due to sales mix changes, the reduction in higher margin PCR VTM and inflationary increases in the price of raw materials.

Research and development expenses declined from $1.1m to $1.0m when compared to Q2, 2021 due to a continued focus on cost control measures. Selling, general and administrative (SG&A) expenses were $6.5m in Q2, 2022, a reduction of $0.1m compared to Q2, 2021. The strengthening of the US Dollar against the Euro in Q2, 2022 has contributed to a reduction in our Euro-denominated SG&A expenses and this was partly offset by transaction related management bonuses and higher travel costs.

An impairment charge of $0.5m was recorded in Q2, 2022, compared to an impairment charge of $6.1m in Q2, 2021. In accordance with the provisions of accounting standards under IFRS, a company is required to carry out periodic impairment reviews in order to determine the appropriate carrying value of its net assets. This period’s review has resulted in a non-cash impairment charge of $0.5m being recognised. A number of factors impacted this calculation including the Company’s share price on June 30, 2022, which was lower than the share price at the time of the prior impairment review (31 December 2021), cash flow projections and net asset values across each of the Company’s individual main business units.

Operating loss for the quarter was $1.4m, which represents a decrease in profitability of $1.6m compared to Q2, 2021 and was attributable to a lower gross profit, partly offset by lower indirect costs and a lower impairment charge.

Financial income for Q2, 2022 was zero compared to $1.0m for Q2, 2021, which was due to a fair value adjustment of the derivatives embedded in the exchangeable notes. There is no equivalent financial income in Q2 2022 because 99.7% of the exchangeable notes were retired in January 2022.

Financial expenses in Q2, 2022 were $8.3m compared to $1.4m in Q2, 2021, an increase of $6.9m. A breakdown of the financial expenses is shown in the table below:

US$m

 

Q2 2022

 

 

 

Q2 2021

 

Penalty for early partial settlement of term loan

 

3.5

 

 

 

-

 

Term loan accretion interest

 

2.1

 

 

 

-

 

Term loan cash interest

 

1.9

 

 

 

-

 

Fair value movement for derivative balances related to term loan

 

0.4

 

 

 

-

 

Accretion interest on IFRS 16 leases

 

0.2

 

 

 

0.2

 

Convertible Note interest

 

0.2

 

 

 

-

 

Exchangeable Notes interest

 

0.0

 

 

 

1.2

 

Total financial expense

 

8.3

 

 

 

1.4

 


In May 2022 the Company made an early partial settlement of the senior secured term loan of $34.5m and in accordance with the term loan’s credit agreement, there was a penalty for early repayment of $3.5m. To date, the Company has benefitted from a cash saving of approximately $2.3m by repaying a portion of the term loan early. The minimum liquidity covenant for the term loan was amended after the early repayment, so that the unrestricted cash balance that the Company is required to maintain was reduced from $5.0m to $2.0m until May 2023.

In Q2, 2022, accretion interest of $2.1m was recorded for the senior secured term loan. The accretion interest is higher in Q2 2022 than the expected run rate because of the early partial settlement of the term loan which resulted in an acceleration of the accretion interest expense under the applicable IFRS accounting provisions.

The loss after tax for continuing operations for the quarter was $9.7m in comparison to a loss of $0.8m for the equivalent period last year. This decrease in profitability of $8.9m was primarily due to lower gross profit, lower other operating income and higher financial expenses this quarter, with the partial early term loan repayment the main driver for the increase in financial expenses.

Loss before interest, tax, depreciation, amortisation and share option expense for the year and excluding impairment charges for Q2 2022 (Adjusted EBITDASO) was $0.5m. This is made up as follows:

 

$m

Operating loss

(1.4)

Impairment charge

0.5

Depreciation

0.1

Amortisation

0.2

Adjusted EBITDA

(0.6)

 

 

Share option expense

0.1

Adjusted EBITDASO

(0.5)


The basic loss per ADS for Q2, 2022 was 28.6 cents versus 3.7 cents in Q2, 2021. For both Q2, 2022 and Q2, 2021, the diluted loss per ADS was the same as the basic loss per ADS as potential issuances of ordinary shares were anti-dilutive as their conversion to ADSs would not increase the loss per ADS.

Use of Non-IFRS Financial Measures
The Company reports financial results in accordance with IFRS. To supplement the consolidated financial statements presented in accordance with IFRS, the Company presents the non-IFRS presentation of Adjusted EBITDA and Adjusted EBITDASO. The Company uses these non-IFRS measures to evaluate and manage the Company’s operations internally. The Company is also providing this information to assist investors in performing additional financial analysis. Reconciliation between the Company's results on a IFRS and non-IFRS basis is provided in a table above.

Investment by MiCo Group

In May 2022, the Company announced the successful closure of a $45.2m investment from MiCo Ltd (“MiCo”). MiCo, a KOSDAQ-listed and Korea-based company, is engaged in the biomedical business through its affiliate MiCo BioMed. The investment consists of an equity investment of $25.2m and a seven-year, unsecured junior convertible note of $20.0m. The convertible note has an interest rate of 1.5%. The convertible note mandatorily converts into ADSs if the volume weighted average price of the Company’s ADSs is at or above $3.24 for any five consecutive NASDAQ trading days.

The convertible loan is accounted for as a compound financial instrument containing both an equity and liability element. The debt component is accounted for at amortised cost in accordance with IFRS 9. At June 30, 2022, the carrying value of the convertible note’s debt component was $13.4m and accretion interest of $120,000 was recognised as a financial expense in the six-months ended June 30, 2022. The equity component of the convertible note is $6.7m and is recorded in the equity section of the Balance Sheet. There is no remeasurement of the equity element following initial recognition.

Liquidity

The Group’s cash balance increased from $10.1m to $10.5m in Q2, 2022, an increase of $0.4m. An investment of $45.2m from the Mico Group was received during the quarter and this was primarily used to fund the $34.5m early repayment of the term loan and a related penalty for the early repayment of $3.5m.

Cash used by operations during Q2, 2022 was $1.9m. During Q2, 2022 the Company had capital expenditure cash outflows of $1.8m and payments for property leases of $0.7m. Interest payments in the quarter were $2.0m.

Q3 2022 Revenue Guidance
Preliminary estimates of revenues for Q3 2022 indicate that revenues are expected to be within the range of approximately $19m to $20m with the expected increase in revenue primarily driven by an expected increase of over 30% in HIV PoC revenue and an approximate 25% increase in revenue in our Life Sciences supply business, Fitzgerald Industries.

TrinScreen HIV Update

  • Since Trinity Biotech received World Health Organisation approval in February 2022 for our new HIV screening product, TrinScreen HIV, we have submitted the product for inclusion on the HIV screening programme of the national HIV rapid algorithm in Kenya. In addition, the pre-submission process has been started in several other African countries.

  • Trinity Biotech chose Kenya as the first country to submit TrinScreen HIV for inclusion in the national HIV algorithm given its large market size, estimated at 5 to 6 million tests per year, and its prestigious and leadership role as an innovator in HIV management in Africa.

  • In Kenya, a technical taskforce appointed by the Ministry of Health to undertake a review of Kenya’s HIV testing algorithm recommended TrinScreen HIV as the first line HIV screening test for Kenya’s new HIV testing algorithm 2022.

  • That Kenya has recommended TrinScreen HIV as the HIV screening test is a significant vote of confidence in TrinScreen HIV and our Africa Team.

  • The use of the new HIV algorithm has been delayed due to (1) the change of government in Kenya following the election in August 2022 and (2) legal objections by competitors regarding the overall HIV algorithm evaluation process.

  • The new government is now in place and we understand they are motivated to scale up the HIV rapid testing programme to pre-COVID-19 levels.

  • We understand the implementation of the new HIV testing algorithm will begin before the end of the year and expect the first order to arrive shortly.

  • Target countries for TrinScreen HIV for active evaluation in 2023 have a combined estimated market size of 30 million tests annually.

Premier Resolution FDA 510k Submission

  • In late August 2022, the Company submitted its 510k submission to the FDA for US regulatory approval of its Premier Resolution Haemoglobin Variants instrument.

  • This product has already been launched in Europe under the CE mark but requires FDA approval in order to be sold in the US and certain other key markets globally.

  • The Company expects to receive 510k approval for the Premier Resolution by Q2 2023 and this should drive further revenue and earnings growth in our Haemoglobins business.

Comments

Commenting, Aris Kekedjian, Chief Executive Officer and Chairman stated “I’m delighted to lead Trinity Biotech at such an exciting time of change and transformation with the shift to decentralised diagnostics. The company has many of the capabilities, and the experience, to become a key platform in this evolving ecosystem. In addition, our prospects in the autoimmune segment are particularly enticing and likely an area of further investment. We continue to enhance our team and streamline our operations to drive agility and efficiency to maximise shareholder value. I look forward to engaging with shareholders in the coming weeks to lay out our strategy for growth and profitability.”

Commenting, John Gillard, Chief Financial Officer stated “The Company made further substantial progress in strengthening its balance sheet and reducing the cash cost of its debt during Q2 2022. Given the hardening of debt markets over the course of 2022 this action has been shown to be timely and beneficial. The Company continues to invest in future growth, especially with the submission for FDA approval for our Premier Resolution and progress in the adoption of our WHO approved TrinScreen HIV product in Africa.”

Forward-Looking Statements

Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of Trinity Biotech to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the results of research and development efforts, risks associated with the outbreak and global spread of the coronavirus (COVID-19), the effect of regulation by the U.S. Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties. For additional information regarding these and other risks and uncertainties associated with Trinity Biotech’s business, reference is made to our reports filed from time to time with the U.S. Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements for any reason.

About Trinity Biotech

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.

Trinity Biotech plc
Consolidated Income Statements

(US$000’s except share data)

 

Three Months Ended
June 30, 2022

(unaudited)

 

 

 

Three Months Ended
June 30, 2021

(unaudited)

 

 

 

Six Months Ended
June 30, 2022

(unaudited)

 

 

 

Six Months Ended
June 30, 2021

(unaudited)

 

 

 

 

 

 

Revenues

 

18,464

 

 

 

25,843

 

 

 

37,240

 

 

 

51,437

 

 

 

 

 

 

Cost of sales

 

(11,937

)

 

 

(14,816

)

 

 

(23,443

)

 

 

(29,497

)

 

 

 

 

 

Gross profit

 

6,527

 

 

 

11,027

 

 

 

13,797

 

 

 

21,940

 

Gross margin %

 

35.3

%

 

 

42.7

%

 

 

37.0

%

 

 

42.7

%

 

 

 

 

 

Other operating income

 

1

 

 

 

2,906

 

 

 

1

 

 

 

2,907

 

 

 

 

 

 

Research & development expenses

 

(984

)

 

 

(1,056

)

 

 

(1,949

)

 

 

(2,493

)

Selling, general and administrative expenses

 

(6,459

)

 

 

(6,591

)

 

 

(13,190

)

 

 

(12,990

)

Impairment charges

 

(519

)

 

 

(6,068

)

 

 

(519

)

 

 

(6,068

)

 

 

 

 

 

Operating (Loss)/Profit

 

(1,434

)

 

 

218

 

 

 

(1,860

)

 

 

3,296

 

 

 

 

 

 

Financial income

 

0

 

 

 

1,018

 

 

 

0

 

 

 

1,019

 

Financial expenses

 

(8,300

)

 

 

(1,364

)

 

 

(20,303

)

 

 

(2,736

)

Net financing expense

 

(8,300

)

 

 

(346

)

 

 

(20,303

)

 

 

(1,717

)

 

 

 

 

 

(Loss)/Profit before tax

 

(9,734

)

 

 

(128

)

 

 

(22,163

)

 

 

1,579

 

 

 

 

 

 

Income tax credit/(expense)

 

29

 

 

 

(655

)

 

 

180

 

 

 

(760

)

Profit/(Loss) for the period on continuing operations

 



(9,705



)

 

 



(783



)

 

 



(21,983



)

 

 



819

 

 

 

 

 

 

Profit/(Loss) for the period on discontinued operations

 



(1



)

 

 



-

 

 

 



(2



)

 

 



-

 

Profit/(Loss) for the period (all attributable to owners of the parent)

 



(9,706



)

 

 



(783



)

 

 



(21,985



)

 

 



819

 

 

 

 

 

 

(Loss)/ Earnings per ADS (US cents)

 

(28.6

)

 

 

(3.7

)

 

 

(75.1

)

 

 

3.9

 

 

 

 

 

 

Diluted (loss)/ earnings per ADS (US cents)

 

(28.6

)

 

 

(3.7

)

 

 

(75.1

)

 

 

3.9

 

 

 

 

 

 

Weighted average no. of ADSs used in computing basic and diluted earnings per ADS

 



33,952,095

 

 

 



20,901,703

 

 

 



29,289,617

 

 

 



20,901,703

 



Trinity Biotech plc
Consolidated Balance Sheets

 

June 30,
2022
US$ ‘000
(unaudited)

March 31,
2022
US$ ‘000
(unaudited)

December 31,
2021
US$ ‘000

ASSETS

 

 

 

Non-current assets

 

 

 

Property, plant and equipment

 

6,261

 

 

 

5,634

 

 

 

5,918

 

Goodwill and intangible assets

 

38,743

 

 

 

37,320

 

 

 

35,981

 

Deferred tax assets

 

4,553

 

 

 

4,478

 

 

 

4,101

 

Derivative financial asset

 

140

 

 

 

219

 

 

 

-

 

Other assets

 

207

 

 

 

175

 

 

 

207

 

Total non-current assets

 

49,904

 

 

 

47,826

 

 

 

46,207

 

 

 

 

 

Current assets

 

 

 

Inventories

 

29,109

 

 

 

29,627

 

 

 

29,123

 

Trade and other receivables

 

15,913

 

 

 

16,898

 

 

 

16,116

 

Income tax receivable

 

1,762

 

 

 

1,734

 

 

 

1,539

 

Cash, cash equivalents and deposits

 

10,453

 

 

 

10,012

 

 

 

25,910

 

Total current assets

 

57,237

 

 

 

58,271

 

 

 

72,688

 

 

 

 

 

TOTAL ASSETS

 

107,141

 

 

 

106,097

 

 

 

118,895

 

 

 

 

 

EQUITY AND LIABILITIES

 

 

 

Equity attributable to the equity holders of the parent

 

 

 

Share capital

 

1,963

 

 

 

1,445

 

 

 

1,213

 

Share premium

 

53,297

 

 

 

21,874

 

 

 

16,187

 

Treasury shares

 

(24,922

)

 

 

(24,922

)

 

 

(24,922

)

Accumulated surplus/(deficit)

 

(9,103

)

 

 

481

 

 

 

12,559

 

Translation reserve

 

(5,439

)

 

 

(5,186

)

 

 

(5,379

)

Other reserves

 

23

 

 

 

23

 

 

 

23

 

Total equity/(deficit)

 

15,819

 

 

 

(6,285

)

 

 

(319

)

 

 

 

 

Current liabilities

 

 

 

Income tax payable

 

21

 

 

 

40

 

 

 

22

 

Trade and other payables

 

13,600

 

 

 

15,637

 

 

 

17,107

 

Exchangeable senior note payable

 

210

 

 

 

210

 

 

 

83,312

 

Provisions

 

50

 

 

 

50

 

 

 

50

 

Total current liabilities

 

13,881

 

 

 

15,937

 

 

 

100,491

 

 

 

 

 

Non-current liabilities

 

 

 

Senior secured term loan

 

43,990

 

 

 

76,246

 

 

 

-

 

Derivative financial liability

 

2,002

 

 

 

1,671

 

 

 

-

 

Convertible Note

 

13,372

 

 

 

-

 

 

 

-

 

Other payables

 

12,723

 

 

 

13,279

 

 

 

13,865

 

Deferred tax liabilities

 

5,354

 

 

 

5,249

 

 

 

4,858

 

Total non-current liabilities

 

77,441

 

 

 

96,445

 

 

 

18,723

 

 

 

 

 

TOTAL LIABILITIES

 

91,322

 

 

 

112,382

 

 

 

119,214

 

 

 

 

 

TOTAL EQUITY AND LIABILITIES

 

107,141

 

 

 

106,097

 

 

 

118,895

 



Trinity Biotech plc
Consolidated Statement of Cash Flows

 

 

Three
Months
Ended
June 30, 2022
(unaudited)

 

 

 

Three Months Ended
June 30, 2021
(unaudited)

 

 

 

Six
Months Ended
June 30, 2022
(unaudited)

 

 

 

Six Months Ended
June 30, 2021
(unaudited)

 

Cash flows from operating activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Profit/(loss) for the period

 

(9,706

)

 

 

(783

)

 

 

(21,985

)

 

 

819

 

Adjustments to reconcile net profit/(loss) to cash provided by operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

47

 

 

 

577

 

 

 

479

 

 

 

1,136

 

Amortisation

 

214

 

 

 

240

 

 

 

442

 

 

 

458

 

Income tax (credit)/expense

 

(29

)

 

 

655

 

 

 

(180

)

 

 

760

 

Financial income

 

-

 

 

 

(1,018

)

 

 

-

 

 

 

(1,019

)

Financial expense

 

8,300

 

 

 

1,364

 

 

 

20,303

 

 

 

2,736

 

Share-based payments

 

122

 

 

 

312

 

 

 

319

 

 

 

693

 

Foreign exchange gains on operating cash flows

 

(191

)

 

 

(276

)

 

 

(149

)

 

 

(67

)

Impairment charge

 

519

 

 

 

6,068

 

 

 

519

 

 

 

6,068

 

Other non-cash items

 

995

 

 

 

(2,774

)

 

 

305

 

 

 

(3,144

)

Net movement on working capital

 

(2,217

)

 

 

(3,155

)

 

 

(3,481

)

 

 

(1,326

)

Cash (used)/generated from operations

 

(1,946

)

 

 

1,210

 

 

 

(3,428

)

 

 

7,114

 

Interest paid

 

(1

)

 

 

(21

)

 

 

(3

)

 

 

(25

)

Interest received

 

2

 

 

 

1

 

 

 

2

 

 

 

2

 

Income taxes received/(paid)

 

13

 

 

 

(72

)

 

 

1

 

 

 

120

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash (used)/generated by operating activities

 

(1,932

)

 

 

1,118

 

 

 

(3,428

)

 

 

7,211

 

Cash flows from investing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Payments to acquire intangible assets

 

(1,658

)

 

 

(1,742

)

 

 

(3,211

)

 

 

(3,288

)

Acquisition of property, plant and equipment

 

(143

)

 

 

(389

)

 

 

(305

)

 

 

(969

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash used in investing activities

 

(1,801

)

 

 

(2,131

)

 

 

(3,516

)

 

 

(4,257

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issue of ordinary share capital including share premium (net of issuance costs)

 

25,019

 

 

 

-

 

 

 

25,019

 

 

 

-

 

Net proceeds from new senior secured term loan

 

-

 

 

 

-

 

 

 

80,014

 

 

 

-

 

Proceeds for convertible note issued

 

20,000

 

 

 

-

 

 

 

20,000

 

 

 

 

 

Expenses paid in connection with debt financing

 

(40

)

 

 

-

 

 

 

(2,356

)

 

 

-

 

Repayment of senior secured term loan

 

(34,500

)

 

 

-

 

 

 

(34,500

)

 

 

-

 

Penalty for early settlement of term loan

 

(3,450

)

 

 

-

 

 

 

(3,450

)

 

 

-

 

Purchase of exchangeable notes

 

-

 

 

 

-

 

 

 

(86,730

)

 

 

-

 

Interest paid on senior secured term loan

 

(1,920

)

 

 

-

 

 

 

(3,706

)

 

 

-

 

Interest paid on convertible note

 

(49

)

 

 

-

 

 

 

(49

)

 

 

-

 

Proceeds from Paycheck Protection loans

 

-

 

 

 

-

 

 

 

-

 

 

 

1,764

 

Interest payment on exchangeable notes

 

(4

)

 

 

(1,998

)

 

 

(1,289

)

 

 

(1,998

)

Payment of lease liabilities

 

(729

)

 

 

(743

)

 

 

(1,500

)

 

 

(1,472

)

Net cash generated/(used) in financing activities

 

4,327

 

 

 

(2,741

)

 

 

(8,547

)

 

 

(1,706

)

Increase/(decrease) in cash and cash equivalents and short-term investments

 

594

 

 

 

(3,754

)

 

 

(15,491

)

 

 

1,248

 

Effects of exchange rate movements on cash held

 

(153

)

 

 

95

 

 

 

34

 

 

 

43

 

Cash and cash equivalents and short-term investments at beginning of period

 

10,012

 

 

 

32,277

 

 

 

25,910

 

 

 

27,327

 

Cash and cash equivalents and short-term investments at end of period

 

10,453

 

 

 

28,618

 

 

 

10,453

 

 

 

28,618

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).


Contact:

Trinity Biotech plc

Lytham Partners, LLC  

 

John Gillard

Joe Diaz

 

(353)-1-2769800

(1)-602-889-9700

 

 

E-mail: investorrelations@trinitybiotech.com